论文部分内容阅读
最近Merck药厂从甲型肝炎病毒CR326F株中开发出一种甲醛灭活、明矾作佐剂的甲型肝炎疫苗,下面介绍这种疫苗免疫接种2～16岁儿童的试验结果。先给200名成人肌肉接种疫苗,证明是安全的,然后再肌肉接种2～16岁的健康儿童(男性56%,女性44%)。他们均无免疫缺陷或肝病史,对一些疫苗成分(如明矾或硫
Recently, Merck Pharmaceuticals developed a formaldehyde-inactivated, alum-adjuvanted Hepatitis A vaccine from the hepatitis C virus CR326F strain. The results of this vaccine immunization of children aged 2-16 years are described below. Vaccination was first given to 200 adult muscles, which proved to be safe, followed by intramuscular inoculation of healthy children aged 2-16 years (56% of males and 44% of females). None of them had a history of immunodeficiency or liver disease, and for some vaccine components (such as alum or sulfur)